Royalty Pharma plc
RPRX
$45.57
$0.771.72%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.38B | 2.35B | 2.31B | 2.26B | 2.26B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.38B | 2.35B | 2.31B | 2.26B | 2.26B |
| Cost of Revenue | -295.84M | -154.91M | -394.65M | 21.72M | 732.46M |
| Gross Profit | 2.67B | 2.50B | 2.70B | 2.24B | 1.53B |
| SG&A Expenses | 676.11M | 554.10M | 492.32M | 289.72M | 236.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 832.27M | 801.19M | 449.67M | 363.45M | 971.13M |
| Operating Income | 1.55B | 1.55B | 1.86B | 1.90B | 1.29B |
| Income Before Tax | 1.32B | 1.30B | 1.66B | 1.77B | 1.33B |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.32K | 1.30K | 1.66K | 1.77K | 1.33K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -553.25M | -537.67M | -644.05M | -675.97M | -471.83M |
| Net Income | 770.95M | 764.96M | 1.02B | 1.09B | 858.98M |
| EBIT | 1.55B | 1.55B | 1.86B | 1.90B | 1.29B |
| EBITDA | 1.01B | 654.92M | 225.49M | -- | -- |
| EPS Basic | 1.67 | 1.64 | 2.19 | 2.34 | 1.81 |
| Normalized Basic EPS | 0.57 | 0.65 | 0.86 | 0.89 | 0.49 |
| EPS Diluted | 1.67 | 1.63 | 2.18 | 2.34 | 1.80 |
| Normalized Diluted EPS | 0.44 | 0.53 | 0.68 | 0.71 | 0.40 |
| Average Basic Shares Outstanding | 1.85B | 1.88B | 1.90B | 1.92B | 1.94B |
| Average Diluted Shares Outstanding | 2.26B | 2.29B | 2.32B | 2.36B | 2.38B |
| Dividend Per Share | 0.88 | 0.87 | 0.86 | 0.85 | 0.84 |
| Payout Ratio | 49.06% | 49.36% | 36.87% | 34.60% | 43.83% |